US0021202025 - Common Stock
Get insights into the top gainers and losers of Tuesday's after-hours session.
aTyr Pharma to Participate in April Investor Conferences...
Penny stocks are incredibly risky. However, if you can handle the heat, these ideas might be worth your while.
LIFE stock results show that aTyr Pharma missed analyst estimates for earnings per share the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips aTyr Pharma (NASDAQ:LIFE) just reported results for the fourth quarter of 2023....
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update ...
Management to host conference call and webcast on March 14th at 5:00 pm EDT / 2:00 pm PDT
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results...
Tyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants...
With proposed FED rate cuts incoming, these are the penny stocks that are likely to see a spark into new rallies.
Dr. Frederick to advise Company on corporate affairs and commercial strategy for efzofitimod in interstitial lung disease (ILD).
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor for efzofitimod program in interstitial lung disease...
Efzofitimod demonstrated immune regulatory function improving disease outcomes and mitigating fibrosis in animal models....
Read about aTyr Pharma's $300M mixed-shelf offering and potential securities issuance, but note that the prospectus is not an offer to sell.
The "Diya Jalao Roshni Lao" campaign was initiated by the Beat of Life Entertainment company in 2022. Its aim is to draw people's attention to our culture, the hard work of potters, hope, their lives, and the benefits of lighting lamps.
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment early in the second quarter of 2024. Phase 2 EFZO-CONNECT™...
aTyr Pharma announces that it will present at two investor conferences in November 2023....
Multiple centers in the U.S. are open for enrollment
Post-hoc analysis from Phase 1b/2a study in pulmonary sarcoidosis presented at the European Respiratory Society (ERS) International Congress 2023.
SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of...
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis currently enrolling in the U.S., Europe and Japan. Phase 2 EFZO-CONNECT™ study of...
Oppenheimer has downgraded aTyr Pharma Inc (NASDAQ: LIFE) to Perform from Outperform, citing a few material catalysts in the next few quarters.
aTyr Pharma (LIFE) lost ~5% on Wednesday after Oppenheimer downgraded it arguing that the biotherapeutics company has only a few catalysts ahead. Read more here.
Bard AI has consistently outperformed, and it has identified seven growth stocks that it believes will deliver triple-digit returns.
Presentations highlight efzofitimod’s novel myeloid-cell focused mechanism and current Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis. SAN DIEGO, June ...
SAN DIEGO, June 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of...
SAN DIEGO, May 25, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of...